Several arguments are in favor of a therapeutic monitoring for the erlotinib, therefore, a
pharmacokinetic (PK) has been prepared using data from the literature. This model must be
validated at concentrations achieved in practice. This is a preliminary study before the
implementation of a randomized trial confirming the therapeutic monitoring of erlotinib
through this model.